Protalix BioTherapeutics, Inc. Deferred Revenue
Protalix BioTherapeutics, Inc. (PLX) had Deferred Revenue of $0 as of 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-03-06
- 2017-09-30: Deferred Revenue, Current $0.00.
- 2017-06-30: Deferred Revenue, Current $1.93M.
- 2017-03-31: Deferred Revenue, Current $1.93M.
- 2016-12-31: Deferred Revenue, Current $837.00K.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.93M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $1.93M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $837.00K 10-K · filed 2018-03-06 | |
| 2016-09-30 | $504.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $504.00K 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $504.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $504.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $6.85M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $6.93M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $7.07M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $886.00K 10-K · filed 2016-03-08 | $6.76M 10-K · filed 2015-03-12 |
| 2014-09-30 | $6.62M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $7.28M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $7.61M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $9.37M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $9.51M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $9.00M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $8.59M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $9.44M 10-K · filed 2014-03-13 | |
| 2012-09-30 | $4.56M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $4.86M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $4.86M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $6.12M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $5.63M 10-Q · filed 2011-11-07 | |
| 2011-06-30 | $6.15M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $4.56M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |